X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

GE sets new standard for monoclonal antibody purification: Up to 40% increase in capacity

Yuvraj_pawp by Yuvraj_pawp
25th September 2017
in Americas, News

GE Healthcare introduces a new Protein A chromatography resin, MabSelect PrismA, which will help biopharmaceutical manufacturers improve their monoclonal antibody (mAb) purification capacity by up to 40 percent (1). The resin is also significantly more alkaline-stable (2), meaning that MabSelect PrismA can be cleaned with a higher concentration of sodium hydroxide to better control cross-contamination and bioburden risks (3).

 

Monoclonal antibody products (mAbs) are the largest and fastest growing segment of biologics; the market revenue is estimated to reach USD 125 billion in 2020 (4). Nearly all mAbs on the market use Protein A resin as the first purification step because it offers an efficient, common platform for different mAbs (5). Protein purification is an obligatory step in biomanufacturing, and the target protein that is extracted from the cell culture is used to make the final biopharmaceutical product.

The efficiency with which cells produce antibodies during the biomanufacturing process has improved radically during the past years, creating pressure on the purification technologies. The result has been increased processing times, and larger consumption of chromatography resins.

MabSelect PrismA addresses a number of key challenges, including the increased upstream titers (6). The new resin is highly efficient due to its excellent binding capacity, which is critical, because it determines how much resin is needed to purify a certain amount of protein.

“Biopharma companies are constantly looking for more ways to increase their output, and Protein A has a critical role to support these efforts. The thorough research and development work that we have carried out to create MabSelect PrismA sets a new standard for mAb purification. To put it simply, with this chromatography resin our customers will be able to produce more biopharmaceuticals out of their existing manufacturing equipment. Protein purification is no longer a bottleneck, but driving higher productivity and shorter manufacturing lead times for our customers,” says Jan Makela, General Manager, BioProcess, GE Healthcare Life Sciences.

MabSelect PrismA has been developed at the GE Healthcare Life Sciences site in Uppsala, Sweden, where the resin is also manufactured. The factory in Uppsala is one of the largest manufacturing facilities for chromatography resins in the world, and between 2017 and 2022 GE is annually investing up to USD 70 million in the production facility to significantly increase its capacity.

GE Healthcare’s customers can order MAbSelect PrismA samples as of today. The product will be fully available for orders during the first half of 2018.

(1) Compared to GE Healthcare Life Sciences’ MabSelect SuRe LX.
(2) Compared to GE Healthcare Life Sciences’ MabSelect SuRe LX.
(3) Bioburden is the degree of microbial contamination or microbial load, the number of organisms contaminating an object (Medical Dictionary for the Health Professions and Nursing)
(4) Ecker DM1, Jones SD, Levine HL (2015): The therapeutic monoclonal antibody market
(5) Downstream processing of monoclonal antibodies—Application of Platform Approaches (2017)
(6) Titer characterizes upstream manufacturing efficiency that indicates that more desired product is manufactured using the same or less amount of fluid or filled bioreactor volume. (BioProcess International: 30 Years of Upstream Productivity Improvements)

Tags: America
Previous Post

Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical Progress with Esaxerenone

Next Post

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship to further upgrade its state-of-the-art production process for TriMix mRNA immunotherapies

Related Posts

Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
America Facing Heart Health Issues Since The Pandemic Began
News

America Facing Heart Health Issues Since The Pandemic Began

8th February 2022
T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants
News

T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants

7th February 2022
OLUMIANT® (baricitinib) 2-mg Tablets gets FDA approval to treat adult patients with moderately to severely active Rheumatoid Arthritis
Manufacturing

Lilly announces $1 billion investment in new manufacturing facility in North Carolina

7th February 2022
Recipharm supports FDA approval of Perrigos AB-rated generic product
News

Recipharm acquires GenIbet to bolster Biologics offering

7th February 2022
Next Post

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship to further upgrade its state-of-the-art production process for TriMix mRNA immunotherapies

Latest News

Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In